Investors Sell DaVita HealthCare Partners Inc. (DVA) on Strength (DVA)
Investors sold shares of DaVita HealthCare Partners Inc. (NYSE:DVA) on strength during trading hours on Thursday. $9.85 million flowed into the stock on the tick-up and $23.16 million flowed out of the stock on the tick-down, for a money net flow of $13.31 million out of the stock. Of all equities tracked, DaVita HealthCare Partners had the 0th highest net out-flow for the day. DaVita HealthCare Partners traded up $0.10 for the day and closed at $64.43
DVA has been the subject of a number of recent analyst reports. Zacks Investment Research lowered shares of DaVita HealthCare Partners from a “hold” rating to a “sell” rating in a research report on Wednesday, July 27th. TheStreet lowered shares of DaVita HealthCare Partners from a “buy” rating to a “hold” rating in a research report on Monday, August 8th. Bank of America Corp. lowered shares of DaVita HealthCare Partners from a “buy” rating to a “neutral” rating and set a $70.00 target price for the company. in a research report on Tuesday. Citigroup Inc. began coverage on shares of DaVita HealthCare Partners in a research report on Tuesday. They issued a “neutral” rating and a $71.00 target price for the company. Finally, JPMorgan Chase & Co. upped their target price on shares of DaVita HealthCare Partners from $74.00 to $75.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 9th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and five have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $76.50.
The company’s 50-day moving average is $70.34 and its 200 day moving average is $73.31. The stock has a market capitalization of $13.33 billion, a PE ratio of 37.48 and a beta of 1.07.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/09/investors-sell-davita-healthcare-partners-inc-dva-on-strength-dva.html
DaVita HealthCare Partners (NYSE:DVA) last announced its quarterly earnings data on Monday, August 8th. The company reported $1.01 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.98 by $0.03. During the same quarter in the previous year, the business earned $0.95 earnings per share. The firm had revenue of $3.72 billion for the quarter, compared to the consensus estimate of $3.67 billion. The firm’s revenue for the quarter was up 8.2% on a year-over-year basis. On average, analysts predict that DaVita HealthCare Partners Inc. will post $3.76 EPS for the current year.
In related news, COO Michael David Staffieri sold 20,262 shares of the firm’s stock in a transaction on Tuesday, August 9th. The shares were sold at an average price of $73.09, for a total transaction of $1,480,949.58. Following the completion of the transaction, the chief operating officer now directly owns 52,279 shares of the company’s stock, valued at $3,821,072.11. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Jeanine Marie Jiganti sold 1,291 shares of the firm’s stock in a transaction on Monday, July 11th. The shares were sold at an average price of $78.51, for a total transaction of $101,356.41. Following the transaction, the insider now directly owns 5,716 shares of the company’s stock, valued at $448,763.16. The disclosure for this sale can be found here. Corporate insiders own 2.10% of the company’s stock.
DaVita HealthCare Partners Company Profile
DaVita HealthCare Partners Inc is a provider of kidney care services. The Company operates Kidney Care division and HealthCare Partners (HCP) division. Its segments include U.S. dialysis and related lab services, HCP and Other-Ancillary services and strategic initiatives. Its Kidney Care division is a provider of dialysis services in the United States, treating patients with chronic kidney failure and end stage renal disease (ESRD).
Receive News & Ratings for DaVita HealthCare Partners Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for DaVita HealthCare Partners Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.